Evidence map›Paper›PMID 28423484›Full record

ArticleOncotarget2017

miR-494-3p overexpression promotes megakaryocytopoiesis in primary myelofibrosis hematopoietic stem/progenitor cells by targeting SOCS6.

Sebastiano Rontauroli, Ruggiero Norfo, Valentina Pennucci, Roberta Zini, Samantha Ruberti, Elisa Bianchi, Simona Salati, Zelia Prudente, Chiara Rossi, Vittorio Rosti and 5 more

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 1 country.

Sebastiano RontauroliCentre for Regenerative Medicine, Life Sciences Department, University of Modena and Reggio Emilia, Modena, Italy.
Ruggiero NorfoCentre for Regenerative Medicine, Life Sciences Department, University of Modena and Reggio Emilia, Modena, Italy.
Valentina PennucciCentre for Regenerative Medicine, Life Sciences Department, University of Modena and Reggio Emilia, Modena, Italy.
Roberta ZiniCentre for Regenerative Medicine, Life Sciences Department, University of Modena and Reggio Emilia, Modena, Italy.
Samantha RubertiCentre for Regenerative Medicine, Life Sciences Department, University of Modena and Reggio Emilia, Modena, Italy.
Elisa BianchiCentre for Regenerative Medicine, Life Sciences Department, University of Modena and Reggio Emilia, Modena, Italy.
Simona SalatiCentre for Regenerative Medicine, Life Sciences Department, University of Modena and Reggio Emilia, Modena, Italy.
Zelia PrudenteCentre for Regenerative Medicine, Life Sciences Department, University of Modena and Reggio Emilia, Modena, Italy.
Chiara RossiCentre for Regenerative Medicine, Life Sciences Department, University of Modena and Reggio Emilia, Modena, Italy.
Vittorio RostiCenter for The Study of Myelofibrosis, Biotechnology Research Area, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy.
Paola GuglielmelliCRIMM-Center for Research and Innovation for Myeloproliferative Neoplasms, AOU Careggi, and Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Giovanni BarosiCenter for The Study of Myelofibrosis, Biotechnology Research Area, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy.
Alessandro VannucchiCRIMM-Center for Research and Innovation for Myeloproliferative Neoplasms, AOU Careggi, and Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Enrico TagliaficoCenter for Genome Research, University of Modena and Reggio Emilia, Modena, Italy.
Rossella ManfrediniCentre for Regenerative Medicine, Life Sciences Department, University of Modena and Reggio Emilia, Modena, Italy.
University of Modena and Reggio Emilia · ITIstituti di Ricovero e Cura a Carattere Scientifico · ITUniversity of Florence · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Primary myelofibrosis (PMF) is a chronic Philadelphia-negative myeloproliferative neoplasm characterized by hematopoietic stem cell-derived clonal myeloproliferation, involving especially the megakaryocyte lineage. To better characterize how the altered expression of microRNAs might contribute to PMF pathogenesis, we have previously performed the integrative analysis of gene and microRNA expression profiles of PMF hematopoietic stem/progenitor cells (HSPCs), which allowed us to identify miR-494-3p as the upregulated microRNA predicted to target the highest number of downregulated mRNAs.To elucidate the role of miR-494-3p in hematopoietic differentiation, in the present study we demonstrated that miR-494-3p enforced expression in normal HSPCs promotes megakaryocytopoiesis. Gene expression profiling upon miR-494-3p overexpression allowed the identification of genes commonly downregulated both after microRNA overexpression and in PMF CD34+ cells. Among them, suppressor of cytokine signaling 6 (SOCS6) was confirmed to be a miR-494-3p target by luciferase assay. Western blot analysis showed reduced level of SOCS6 protein as well as STAT3 activation in miR-494-3p overexpressing cells. Furthermore, transient inhibition of SOCS6 expression in HSPCs demonstrated that SOCS6 silencing stimulates megakaryocytopoiesis, mimicking the phenotypic effects observed upon miR-494-3p overexpression. Finally, to disclose the contribution of miR-494-3p upregulation to PMF pathogenesis, we performed inhibition experiments in PMF HSPCs, which showed that miR-494-3p silencing led to SOCS6 upregulation and impaired megakaryocyte differentiation.Taken together, our results describe for the first time the role of miR-494-3p during normal HSPC differentiation and suggest that its increased expression, and the subsequent downregulation of its target SOCS6, might contribute to the megakaryocyte hyperplasia commonly observed in PMF patients.

Indexed as

Blotting, WesternElectroporationGene Expression ProfilingGene Expression Regulation, NeoplasticHematopoietic Stem CellsHumansImmunophenotypingMicroRNAsPolymerase Chain ReactionPrimary MyelofibrosisSuppressor of Cytokine Signaling ProteinsThrombopoiesisTranscriptomeMicroRNAsMIRN494 microRNA, humanSOCS6 protein, humanSuppressor of Cytokine Signaling ProteinsCD34+ cellsmegakaryocytopoiesismiR-494-3pprimary myelofibrosisSOCS6

Identifiers

PMID28423484
PMCPMC5400591
OpenAlexW2589084429

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.